肝脏 ›› 2025, Vol. 30 ›› Issue (6): 862-867.

• 其他肝病 • 上一篇    下一篇

C反应蛋白/白蛋白比值联合血小板与淋巴细胞比值预测恶性梗阻性黄疸介入治疗患者预后的价值

李光林, 李恒, 程勋, 杨贵彬, 罗大勇   

  1. 236015 安徽 阜阳市第二人民医院肝胆胰外科
  • 收稿日期:2024-05-30 出版日期:2025-06-30 发布日期:2025-08-08
  • 通讯作者: 罗大勇,Email:fyldy7172@sina.com
  • 基金资助:
    安徽省自然科学基金(2008085QG345)

The predictive value of C-reactive protein/albumin ratio combined with platelet-to-lymphocyte ratio for the prognosis of patients with malignant obstructive jaundice after interventional therapy

LI Guang-lin, LI Heng, CHENG Xun, YANG Gui-bin, LUO Da-yong   

  1. Department of Hepatobiliary Pancreatic Surgery,No.2 People's Hospital of Fuyang City, Anhui 236015,China
  • Received:2024-05-30 Online:2025-06-30 Published:2025-08-08
  • Contact: LUO Da-yong, Email:fyldy7172@sina.com

摘要: 目的 分析C反应蛋白/白蛋白比值(CAR)联合血小板与淋巴细胞比值(PLR)对行介入治疗的恶性梗阻性黄疸(MOJ)患者预后的预测价值。方法 回顾性分析2020年5月至2023年2月在阜阳市第二人民医院诊治的87例行介入治疗的MOJ患者。根据介入术后1年内生存情况分为预后良好组和预后不良组。测定治疗前CAR、PLR水平,并收集其他临床相关资料,分析患者预后的影响因素。CAR、PLR对患者预后的预测价值用受试者工作特征(ROC)曲线下面积(AUC)进行分析;Kaplan-Meier进行生存曲线分析。结果 预后不良组vs预后良好组显示,年龄[(66.27±7.22)vs(62.35±6.91)岁]、梗阻时间>20 d占比[62.50% vs 38.46%]、CAR[(1.76±0.34)vs(1.15±0.23)]、PLR[(0.77±0.19)vs(0.51±0.13)]、Child-Pugh分级C级占比[31.25% vs 7.69%],预后不良组高于预后良好组,术后抗肿瘤占比[20.83% vs 58.97%],预后不良组低于预后良好组(P<0.05)。logistic回归显示,CAR水平(OR=6.241,95%CI:2.310~16.858)、PLR水平(OR=4.937,95%CI:1.919~12.698)、Child-Pugh分级(OR=2.388,95%CI:1.174~4.854)是影响患者预后的独立危险因素,术后抗肿瘤治疗(OR=0.252,95%CI:0.112~0.566)是保护因素(P<0.05)。ROC曲线显示,CAR、PLR及二者联合对预后预测的敏感度分别为70.80%、75.00%、89.60%,特异性分别为74.40%、71.80%、87.20%,AUC分别为0.794、0.807、0.890(P<0.05)。CAR、PLR高、低表达患者生存曲线存在统计学差异(P<0.05)。结论 CAR、PLR是MOJ患者介入术后预后的独立危险因素,通过联合测定CAR、PLR水平可有效预测患者预后情况。

关键词: 恶性梗阻性黄疸, 经内镜逆行性胰胆管造影术, 胆道支架置入术, C反应蛋白与白蛋白比值, 血小板与淋巴细胞比值

Abstract: Objective To analyze the prognostic value of C-reactive protein/albumin ratio (CAR) combined with platelet to lymphocyte ratio (PLR) in malignant obstructive jaundice (MOJ) after interventional therapy. Methods A total of 87 MOJ patients who underwent interventional therapy in the No.2 People’s Hospital of Fuyang City from May 2020 to February 2023 were retrospectively selected in the study. The patients were divided into good prognosis group and poor prognosis group according to the survival status within 1 year after interventional therapy. CAR and PLR were measured before treatment, and other clinical data were collected to analyze the prognostic factors of patients. The predictive value of CAR and PLR for the prognosis of patients was analyzed by the area under the receiver operating characteristic (ROC) curve (AUC). The survival curve was analyzed by Kaplan-Meier method. Results In the poor prognosis group, age [(66.27±7.22) years vs (62.35±6.91) years], obstruction time > 20 days accounted for [62.50% vs 38.46%], CAR[(1.76±0.34) vs (1.15±0.23)], PLR[(0.77±0.19) vs (0.51±0.13)] and Child-Pugh grade C [31.25% vs 7.69%] were higher than those in good prognosis group, the proportion of anti-tumor after operation [20.83% vs 58.97%] was lower than that in the group with good prognosis (P<0.05). Multivariate stepwise Logistic regression analysis showed that CAR level (OR=6.241, 95%CI: 2.310~16.858), PLR level (OR=4.937, 95%CI: 1.919~12.698), Child-Pugh classification (OR=2.388, 95%CI: 1.174~4.854) were independent risk factors for the prognosis of patients, and postoperative antineoplastic therapy (OR=0.252, 95%CI: 0.112~0.566) was an independent protective factor (P<0.05). ROC curve showed that the sensitivity of CAR, PLR and the combination of the two to predict the prognosis of patients was 70.80%, 75.00%, 89.60%, respectively, the specificity was 74.40%, 71.80%, 87.20%, respectively, and the AUC was 0.794, 0.807, 0.890, respectively (P<0.05). The survival curves of patients with high and low expressions of CAR and PLR were statistically different (P<0.05). Conclusion CAR, PLR are independent risk factors of postoperative outcomes in MOJ patients, through joint determination CAR and PLR level can effectively predict the patients′ prognosis.

Key words: Malignant obstructive jaundice, Endoscopic retrograde cholangiopancreatography, Biliary stent placement, C-reactive protein/albumin ratio, Platelet to lymphocyte ratio